Characterization of the common genetic variation in the Spanish population of Navarre

Authors:
Alberto Maillo, alberto.ruizdeinfante@kaust.edu.sa, Spain[1,2]
Estefania Huergo, ehuergoi@navarra.es, Spain[1,#]
María Apellániz-Ruiz, mv.apellaniz.ruiz@navarra.es, Spain[3,#]
Edurne Urrutia, eurrutil@navarra.es, Spain[1,3,#]
María Miranda, mmirandp@navarra.es, Spain[3]
Josefa Salgado, jsalgadg@navarra.es, Spain[3,4,5]
Sara Pasalodos-Sánchez, spasalos@navarra.es, Spain[3]
Luna Delgado-Mora, lunadelde@gmail.com, Spain[3,6]
Óscar Teijido, oteijidh@navarra.es, Spain[3]
Ibai Goicoechea, igoicoeo@nasertic.es, Spain[7]
Rosario Carmona, rosariom.carmona@juntadeandalucia.es, Spain[8,9,10,11]
Javier Perez-Florido, javier.perez.florido.sspa@juntadeandalucia.es, Spain[8,9,10,11]
Virginia Aquino, virginia.aquino@juntadeandalucia.es, Spain[8]
Daniel Lopez-Lopez, daniel.lopez.lopez@juntadeandalucia.es, Spain[8,9,11]
María Peña-Chilet, maria_pena@iislafe.es, Spain[8,11]
Sergi Beltrán, sergi.beltran@cnag.eu, Spain[12,13,14]
Joaquín Dopazo, joaquin.dopazo@juntadeandalucia.es, Spain[8,9,10,11]
Iñigo Lasa, ilasa@unavarra.es, Spain[15]
Juan José Beloqui, jj.beloqui.lizaso@navarra.es, Spain[3]
NAGEN-scheme, (*see list at the end*),
Ángel Alonso, aalonsos@navarra.es, Spain[3*]
David Gomez-Cabrero, david.gomez.cabrero@navarra.es, Spain[1,2*]

Affiliations:

1: Translational Bioinformatics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
2: Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
3: Genomics Medicine Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
4: Servicio de Genética Médica-Hospital Universitario de Navarra (HUN), Pamplona, Spain.
5: Dp. Bioquímica y Biología Molecular-Universidad Pública de Navarra (UPNA), Pamplona, Spain.
6: Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain.
7: Department of Personalized Medicine, NASERTIC, Government of Navarra, Pamplona, Spain.
8: Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Sevilla, Spain.

9: Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocio/CSIC/University of Sevilla, Sevilla, Spain.
10: FPS/ELIXIR-ES, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, Sevilla, Spain.
11: Biomedical Research Networking Center in Rare Diseases (CIBERER), Health Institute Carlos III, 28029 Madrid, Spain.
12: CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
13: Universitat Pompeu Fabra (UPF), Barcelona, Spain.
14: Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona (UB), Barcelona, Spain.
15: Laboratory of Microbial Pathogenesis, Navarrabiomed, Pamplona, Spain.

*corresponding. [#]contributed equally

ABSTRACT

Large-scale genomic studies have significantly increased our knowledge of genetic variability across populations. Regional genetic profiling is essential for distinguishing common benign variants from disease-causing ones. To this end, we conducted a comprehensive characterization of exonic variants in the population of Navarre (Spain), utilizing whole genome sequencing data from 358 unrelated individuals of Spanish origin. Our analysis revealed 61,410 biallelic single nucleotide variants (SNV) within the Navarrese cohort, with 35% classified as common (MAF > 1%). By comparing allele frequency data from 1000 Genome Project (excluding the Iberian cohort of Spain, IBS), Genome Aggregation Database, and a Spanish cohort including IBS individuals as well as data from Medical Genome Project, we identified 1,069 SNVs common in Navarre but rare (MAF ≤ 1%) in all other populations. This observation was further corroborated by a second regional cohort of 239 unrelated exomes, which confirmed 676 of the 1,069 SNVs as common in Navarre. In conclusion, this study highlights the importance of population-specific characterization of genetic variation to improve allele frequency filtering in sequencing data analysis to identify disease-causing variants.

Keywords: personalized medicine, whole genome sequencing WGS, whole exome sequencing WES, single nucleotide variant SNV, population frequencies, genetic variability.

INTRODUCTION

In recent years, the use of NGS in patient healthcare has increased due to technological advances, cost reduction, and enhanced efficiency (1). The advancement of NGS spans a spectrum of applications, encompassing whole exome/genome sequencing (WES/WGS). These technologies revealed a wealth of genetic variants, necessitating the implementation of filters to narrow down the list of candidate variants. In this regard, the availability of population-specific catalogues of common variants enables the identification of rare variants (2), such as the international initiatives 1000 Genome Project (1KGP) (3) and Genome Aggregation Database (gnomAD) (4). Moreover, various countries like the UK (5), USA (6), and Japan (7) have established their databases. In Spain, for instance, the Medical Genome Project (MGP) compiles data from unrelated healthy individuals (8)(9).

In Navarre, a 650,000 population region of north-eastern Spain, the local Government supported the "*NAGEN scheme*" to integrate genomic data analysis into the regional public healthcare system. Nowadays, NAGEN has generated numerous WES/WGS and associated phenoclinical profiles in seven projects, including *NAGEN1000*, focused on rare diseases, and *pharmaNAGEN* on pharmacogenomics in patients with inflammatory bowel diseases (10). The NAGEN strategy's success hinges on identifying population-specific common variants to establish a comprehensive Navarrese population frequency catalogue.

In this study (Fig. 1), we aimed to identify and characterize common exonic variants specific to the Navarrese population. Firstly, we identified common single nucleotide variants (SNVs) in Navarre and rare in other populations. Secondly, we validated the allele frequency of these

95 variants in another Navarrese cohort with only exome data. Finally, the resulting variants were
96 annotated using genomic databases, and their clinical and pharmacological effects and
97 pathogenicity were assessed. Additionally, we conducted functional enrichment analyses to
98 provide further insights. The results will significantly contribute to advancing personalized
99 medicine in Navarre.

100 ## MATERIAL AND METHODS

101 Please refer to the Supplementary information for detailed material and methods.

102 **Referenced population projects**

103 Population frequencies were obtained from 1) gnomAD: genomes v2.1.1; 2) *1KGP_noIBS*: mean
104 1KGP (phase3) population's frequencies, excluding the IBS cohort; and 3) *spain*: combining the
105 MGP and IBS frequencies.

106 **Variant annotation**

107 Variants were annotated using ANNOVAR (11). Clinical and pharmacological relevance was
108 assessed using ClinVar (12), Online Mendelian Inheritance in Man (OMIM) (13) and PharmGKB
109 (14). Variant classification was conducted following the American College of Medical Genetics
110 (ACMG) guidelines (15).

111

112 # RESULTS

113 ## Navarrese discovery cohort

114 The *NAGEN1000* WGS Navarrese project comprised 688 individuals from 294 families (mainly
115 trios) with a rare disease. The WGS was conducted with a mean coverage of 30X, providing
116 comprehensive genomic data across the entire genome. For our study, we kept a subset of this
117 cohort satisfying two criteria: unrelatedness and Spanish ancestry. This result yielded 358
118 individuals, referred to as NAVARREsel.

119 Then, biallelic SNVs on chromosomes 1 to 22, from the exonic region covered by Nextera Exome
120 Enrichment kit, were extracted. Subsequently, we filtered out variants with read depth < 10,
121 genotype quality < 50, or missing genotype in at least one sample. Additionally, sites significantly
122 deviated from Hardy-Weinberg equilibrium (HWE, p-value < 10^{-5}) were removed (16). Finally,
123 61,410 SNVs remained; 21,174 were identified as common variants (MAF > 1%). We observed
124 that including additional individuals did not reveal new common variants, and 21,174 were
125 achieved when considering over 100 individuals (Fig. S1a).

126

127 ## Genetic variation between Navarre, Spanish, and global populations

128 We performed a principal component analysis on the shared variants between NAVARREsel,
129 1KGP, and MGP to depict its relationship. We observed a clear distinction between Navarre and
130 Asian/African populations, reflecting established genetic differences (Fig. 2a). Conversely, an
131 overlap is observed between Navarre and European populations, emphasizing their genetic
132 affinity. Thus, focusing on European populations (Fig. 2b), we observed that Navarrese individuals
133 are close to the Spanish populations (IBS and MGP) and exhibit proximity to Italian individuals.

134 To further analyse the genetic differentiation, we calculated the mean pairwise F_{ST} values. The
135 lower F_{ST} value indicates greater similarity between populations. This occurred when comparing
136 Navarre with the Spanish ($F_{ST(Navarre-IBS)}$ = 0.0001 and $F_{ST(Navarre-MGP)}$ = 0.0007) and Italian ($F_{ST(Navarre-}$
137 $_{TSI)}$ = 0.0014) populations. In contrast, the highest differentiation was observed against East-Asian
138 and African populations ($F_{ST(Navarre-EAS)}$ = 0.0328, $F_{ST(Navarre-AFR)}$ = 0.0434).
139 These findings, aligning with biological expectations, underscore the regional and continental
140 genetic affinities, providing insights into historical populations and evolutionary dynamics.
141

142 ## Exclusive common variants in Navarre

143 To identify exclusive Navarrese common variants, we examined allele frequency among Navarre
144 population and the referenced population: *1KGP_noIBS*, gnomAD, and *spain*. A comparison of the
145 MAF revealed that most variants (17,532 SNVs) were classified as common (MAF > 1%) across the
146 four populations. However, 835 variants exhibited higher prevalence solely in Spanish cohorts
147 (Navarre and *spain*). Specifically, 1,069 SNVs were identified as common in Navarre, and rare
148 (MAF ≤ 1%) in the rest (Fig. 3a).
149 To validate these 1,069 variants, we used the NAVARREval cohort, a subset of 239 WES unrelated
150 individuals of Spanish descent from the current Navarrese population and diagnosed with Crohn's
151 disease (159/239) or ulcerative colitis (86/239) (*pharmaNAGEN* project). Before validation, we
152 assessed the association of these SNVs with these conditions by cross-referencing them with
153 reported variants in the Inflammatory Bowel Disease database, which catalogues variants highly
154 linked to the mentioned diseases (17). The absence of the 1,069 SNVs in this database ensured
155 an unbiased and robust validation process.

156 Among the 1,069 variants initially identified, 998 were detected in NAVARREval with a call rate
157 greater than 80% and demonstrated conformity to HWE. Notably, 676/998 of these SNVs (68%;
158 p-value = $2.2e^{-16}$) were consistently classified as common in NAVARREval, confirming their
159 prevalence within the Navarrese population (variants' information in Table S2). The validation
160 cohort was sufficient to validate the Navarrese common variants, reaching a plateau in Fig. S1b.
161 On the contrary, within the non-validated subset (322/998, 32%), 134 SNVs exhibited MAFs in
162 NAVARREsel that did not exceed a 2-fold difference in NAVARREval, indicating close MAF between
163 both datasets (Fig. S2). This exploration of MAF patterns ensures a comprehensive understanding
164 of the genetic landscape within the Navarre population and its stability across different datasets.
165

166 ## Characterization of common Navarrese variants

167 The annotation of the 676 common Navarrese SNVs revealed 227 synonymous, 371 missense,
168 and five loss-of-function (LoF) variants. These LoF variants were not reported in ClinVar database
169 (12) and were located in five distinct genes without an associated phenotype, according to OMIM
170 (13). Following the ACMG guidelines for variant classification, four were classified as variants of
171 uncertain significance (VUS) and one as benign (15).
172 Clinically, 264/676 reported in ClinVar: 1/264 as a risk factor, 181/264 as benign/likely-benign,
173 32/264 as VUS, 48/264 as having conflicting interpretations, and 2/264 as likely-pathogenic.
174 These likely-pathogenic missense variants were in *SCNN1B* [c.1688G>A p.Arg563Gln;
175 $MAF_{NAVARREsel}$=0.013, $MAF_{NAVARREval}$=0.016] and in *PTGIS* [c.824G>A p.Arg275Gln;
176 $MAF_{NAVARREsel}$=0.013, $MAF_{NAVARREval}$=0.021], associated with "low renin hypertension" and
177 "childhood-onset schizophrenia" respectively, according to ClinVar. The evidence supporting

178 these associations is limited, with a score of 1 out of 4 and reviewed by a single submitter record.
179 Additionally, given its notable prevalence in the Navarrese population, observed in healthy and
180 affected (not related to this phenotype) individuals, these variants might be reconsidered and
181 reclassified as VUS under the ACMG guidelines.
182 Moreover, common Navarrese variants showed no impact on drug metabolism/efficacy,
183 according to PharmGKB (14). Further in silico and enrichment analysis are detailed in
184 Supplementary information.
185

186 ## Refining disease-causing variant identification in the Navarrese population

187 We identified common variants in the Navarrese population, highlighting the importance of
188 population-specific in advancing personalized medicine. The aim was to improve the
189 identification of disease-causing variants during genetic diagnosis using NGS. Therefore, we
190 selected 127 WGS patients from Navarre diagnosed with rare disorders and extracted exonic SNVs
191 on chromosomes 1 to 22, averaging 8,871 variants per patient.
192 We refined the variant list by excluding common variants from *1KGP_noIBS*, gnomAD, *spain*, and
193 Navarre. The Navarrese filtering emerged as the most stringent, resulting in 2.1% of the initial set,
194 compared to 2.7% with gnomAD, 2.9% with *spain* frequencies, and the least restrictive, 4.9% with
195 *1KGP_noIBS* (Fig. 3). This underscores the effectiveness of Navarrese-specific filter in prioritizing
196 and streamlining genetic investigations.
197

198 ## DISCUSSION

199 In this study, we aimed to enhance diagnostic precision in the Navarrese population by exploring
200 common population-specific variants. Utilizing WGS data from 358 individuals of Navarre, we
201 identified 61,410 SNVs, with 21,174 common. Genetic analysis shows affinity with European
202 populations and low differentiation with Spanish populations.

203 Focusing on exclusively common variants in Navarre compared with referenced populations, we
204 obtained 1,069 SNVs, of which 676 were validated in another Navarrese cohort. None showed
205 clinical or pharmacological relevance beyond what was observed in the Spanish population (18).
206 This aligns with the expectation that common population variants are less likely to be associated
207 with disease ethology.

208 Our findings underscore the relevance of considering population-specific factors in genomic
209 diagnostics, which provides complementary insights alongside pangenome references (19). By
210 identifying and excluding common variants within the Navarrese population, we have successfully
211 refined the identification of potential disease-causing variants, contributing to the advancement
212 of personalized medicine for individuals from Navarre. Further research will enhance these
213 insights for broader applications.

DATA AVAILABILITY

Data is available from the corresponding author upon reasonable request.

REFERENCES

1. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology (Basel). 2023 Jul 13;12(7):997.
2. Fattahi Z, Beheshtian M, Mohseni M, Poustchi H, Sellars E, Nezhadi SH, et al. Iranome: A catalog of genomic variations in the Iranian population. Hum Mutat. 2019 Nov 17;40(11):1968–84.
3. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature. 2010 Oct 28;467(7319):1061–73.
4. Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, Solomonson M, et al. Variant interpretation using population databases: Lessons from gnomAD. Hum Mutat. 2022 Aug 16;43(8):1012–30.
5. Smetana J, Brož P. National Genome Initiatives in Europe and the United Kingdom in the Era of Whole-Genome Sequencing: A Comprehensive Review. Genes (Basel). 2022 Mar 21;13(3):556.
6. Ramirez AH, Sulieman L, Schlueter DJ, Halvorson A, Qian J, Ratsimbazafy F, et al. The All of Us Research Program: Data quality, utility, and diversity. Patterns. 2022 Aug;3(8):100570.
7. Mitsuhashi N, Toyo-oka L, Katayama T, Kawashima M, Kawashima S, Miyazaki K, et al. TogoVar: A comprehensive Japanese genetic variation database. Hum Genome Var. 2022 Dec 12;9(1):44.

237 8. Dopazo J, Amadoz A, Bleda M, Garcia-Alonso L, Alemán A, García-García F, et al. 267
238 Spanish Exomes Reveal Population-Specific Differences in Disease-Related Genetic
239 Variation. Mol Biol Evol. 2016;33(5):1205–18.
240 9. Peña-Chilet M, Roldán G, Perez-Florido J, Ortuño FM, Carmona R, Aquino V, et al. CSVS, a
241 crowdsourcing database of the Spanish population genetic variability. Nucleic Acids Res.
242 2021 Jan 8;49(D1):D1130–7.
243 10. NAGEN | Navarrabiomed [Internet]. [cited 2023 Nov 28]. Available from:
244 https://www.navarrabiomed.es/en/nagen
245 11. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from
246 high-throughput sequencing data. Nucleic Acids Res. 2010 Sep 1;38(16):e164–e164.
247 12. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public
248 archive of relationships among sequence variation and human phenotype. Nucleic Acids
249 Res. 2014 Jan;42(Database issue):D980-5.
250 13. Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick's Online Mendelian Inheritance in
251 Man (OMIM(R)). Nucleic Acids Res. 2009 Jan 1;37(Database):D793–6.
252 14. Thorn CF, Klein TE, Altman RB. PharmGKB: The Pharmacogenomics Knowledge Base. In
253 2013. p. 311–20.
254 15. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines
255 for the interpretation of sequence variants: a joint consensus recommendation of the
256 American College of Medical Genetics and Genomics and the Association for Molecular
257 Pathology. Genetics in Medicine. 2015 May;17(5):405–24.

258 16. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality
259 control in genetic case-control association studies. Nat Protoc. 2010 Sep 26;5(9):1564–73.
260 17. Khan F, Radovanovic A, Gojobori T, Kaur M. IBDDB: a manually curated and text-mining-
261 enhanced database of genes involved in inflammatory bowel disease. Database. 2021 Apr
262 30;2021.
263 18. Nunez-Torres R, Pita G, Peña-Chilet M, López-López D, Zamora J, Roldán G, et al. A
264 Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population:
265 From Genetic Characterisation to Clinical Impact. Pharmaceutics. 2023 Apr
266 19;15(4):1286.
267 19. Liao WW, Asri M, Ebler J, Doerr D, Haukness M, Hickey G, et al. A draft human
268 pangenome reference. Nature. 2023 May 11;617(7960):312–24.
269
270

FUNDING

NAGEN1000 and PharmaNAGEN were supported by Navarra Gov (Dirección General de Industria, Energia y Proyectos Estrategicos S3). GRANTS_NUMBERS: 0011-1411-2017-000032, 0011-1411-2018-000047.

AUTHOR INFORMATION

Authors and Affiliations

Translational Bioinformatics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
Alberto Maillo, Estefania Huergo, Edurne Urrutia & David Gomez-Cabrero

Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia
Alberto Maillo & David Gomez-Cabrero

Genomics Medicine Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
María Apellániz-Ruiz, Edurne Urrutia, María Miranda, Josefa Salgado, Sara Pasalodos-Sánchez, Luna Delgado-Mora, Óscar Teijido, Juan José Beloqui & Ángel Alonso

Servicio de Genética Médica-Hospital Universitario de Navarra (HUN), Pamplona, Spain
Josefa Salgado

Dp. Bioquímica y Biología Molecular-Universidad Pública de Navarra (UPNA), Pamplona, Spain
Josefa Salgado

Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain
Luna Delgado-Mora

Department of Personalized Medicine, NASERTIC, Government of Navarra, Pamplona, Spain.
Ibai Goicoechea

Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Sevilla, Spain.
Rosario Carmona, Javier Perez-Florido, Virginia Aquino, Daniel Lopez-Lopez, María Peña-Chilet & Joaquín Dopazo

Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocio/CSIC/University of Sevilla, Sevilla, Spain.
Rosario Carmona, Javier Perez-Florido, Daniel Lopez-Lopez & Joaquín Dopazo

FPS/ELIXIR-ES, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, Sevilla, Spain.
Rosario Carmona, Javier Perez-Florido & Joaquín Dopazo

Biomedical Research Networking Center in Rare Diseases (CIBERER), Health Institute Carlos III, 28029 Madrid, Spain

Rosario Carmona, Javier Perez-Florido, Daniel Lopez-Lopez, María Peña-Chilet & Joaquín Dopazo

CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain
Sergi Beltrán

Universitat Pompeu Fabra (UPF), Barcelona, Spain
Sergi Beltrán

Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona (UB), Barcelona, Spain
Sergi Beltrán

Laboratory of Microbial Pathogenesis, Navarrabiomed, Pamplona, Spain
Iñigo Lasa

Contributions

Conceptualisation (AM, AA, DGC); Clinical and sample collection: (MM, LDM, OT, JS, MAR, SPS); Formal analysis (AM, RC, JPF, VA, DLL, MPC); Data curation (AM); Investigation (AM, EH, MAR, EU, DGC); Funding acquisition (JB, AA); Visualisation (AM, EH, MAR, EU); Writing-original draft (AM, EH, MAR, EU, DGC) Writing-review & editing (AM, MAR, EH, EU, SB, SPS, IG, JD, IL, JB, AA, DGC).

Corresponding authors

Correspondence to Ángel Alonso & David Gomez-Cabrero.

NAGEN scheme

Name	Department	NAGEN project
Anda Apiñaniz, Emma	Servicio de Endocrinología y Nutrición, HUN	NAGEN 1,000

Artigas López, Mercedes	Servicio de Genética Médica, HUN	NAGEN 1,000
Bandrés Elizalde, Eva	Servicio de Hematología, HUN	NAGEN 1,000
Basurte Elorz, Mª Teresa	Servicio de Cardiología, CHN	NAGEN 1,000
Brennan, Paul	NENC NHS Genomic Medicine Centre. Newcastle upon Tyne, UK.	NAGEN 1,000
Celaya Lecea, Concepción	Subdirección de Farmacia, SNS-O	PharmaNAGEN
Cuesta Zorita, Manuel Jesús	Servicio de Psiquiatría, Salud mental	NAGEN 1,000
Curi Chercoles, Sergio Miguel	Servicio de Neumología, HUN	NAGEN 1,000
De la Cruz Sánchez, Susana	Servicio de Oncología Médica, HUN	NAGEN 1,000
Erviti López, Juan	Subdirección de Farmacia, SNS-O	PharmaNAGEN
Fanlo Mateo, Patricia	Servicio de Medicina Interna, HUN	NAGEN 1,000
González, Luis Angel	AVANTIA 400+.	NAGEN 1,000
Gonzalo Etayo	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000
Gorricho Mendívil, Javier	Subdirección de Farmacia, SNS-O	PharmaNAGEN

Guerra Lacunza, Ana	Servicio de Aparato Digestivo, HUN	NAGEN 1,000
Gut, Ivo	Centro Nacional de Análisis Genómicos CNAG. Spain	NAGEN 1,000
Ibáñez Bosch, Rosario	Servicio de Endocrinología y Nutrición, HUN	NAGEN 1,000
Jiménez, Jorge	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000
Lasheras, Gorka	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000
Lorea Bueno	Pharmamodelling	PharmaNAGEN
Maite Sarobe Carricas	Servicio de Farmacia Hospitalaria, HUN	PharmaNAGEN
Mendioroz Iriarte, Maite	Servicio de Neurología, HUN	NAGEN 1,000
Molinuevo Ruiz de Zarate, José Ignacio	Servicio de Oftalmología, HUN	NAGEN 1,000
Montes Díaz, Marta	Servicio de Anatomía Patológica, HUN	NAGEN 1,000
Navarro, Adela	Servicio de Cardiología, HUN	PharmaNAGEN
Onintza Sayar	Pharmamodelling	PharmaNAGEN
Pinillos, Iñaki	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000

Purroy Irurzon, Carolina Eugenia	Servicio de Nefrología, HUN	NAGEN 1,000
Sagaseta de Ilurdoz Uranga, Mª Josefa	Servicio de Pediatría, HUN	NAGEN 1,000
Santesteban Muruzabal, Raquel	Servicio de Dermatología, HUN	NAGEN 1,000
Vicuña, Miren	Servicio de Digestivo, HUN	PharmaNAGEN
Viguria, Mª Cruz	Servicio de Hematología, HUN	PharmaNAGEN
Yoldi Petri, Mª Eugenia	Servicio de Pediatría, HUN	NAGEN 1,000
Zubicaray Ugarteche, José Jacinto	Servicio de Otorrinolaringología, HUN	NAGEN 1,000
Zudaire, Maite	Servicio de Hematología, HUN	PharmaNAGEN

331

332 ## ETHICS DECLARATIONS

333 Competing interests:

334 The authors declare no competing interests.

335 Ethics approval:

336 NAGEN1000 and PharmaNAGEN were approved by Navarra Ethics Committee for Clinical

337 Research (CEIC Navarra).

338 ## FIGURES LEGENDS

339 **Figure 1**: Workflow of this study. Abbreviations: *MGP*, Medical Genome Project; *1KGP*, 1000
340 Genomes Project; *1KGP_noIBS*, 1000 Genomes Project without Iberian population; *gnomAD,*
341 Genome Aggregation Database; *MAF*, minor allele frequency; *SNV*, single nucleotide variant; *SNP*,
342 single nucleotide polymorphism; *WGS*, whole genome sequencing; *WES*, whole exome
343 sequencing; *LoF*, Loss-of-function; HPO, Human Phenotype Ontology; BP, biological process.

344 **Figure 2: a)** Principal component analysis of overlapped variants between NAVARREsel, MGP, and
345 1KGP (including all populations), and coloured by superpopulations. **b)** Principal component
346 analysis of overlapped variants between NAVARREsel, MGP, and 1KGP (including exclusively
347 European populations). Abbreviations: *PCA*, principal component analysis; AFR, African
348 populations; AMR, American populations; EAS, east-Asian populations; SAS, south-Asian
349 populations; EUR, European populations; IBS, Iberian populations in Spain; MGP, Medical
350 Genome Project; TSI, Toscani in Italy; CEU, Utah residents with Northern and Western European
351 ancestry; GBR, British in England and Scotland; FIN, Finnish in Finland.

352 **Figure 3: a)** Upset plot of common variants (MAF > 1%) of each population: NAVARREsel, *spain*,
353 *1KGP_noIBS*, and gnomAD **b)** Resulting percentage of variants per patient (n=127) after removing
354 common variants from Navarre, *spain*, gnomAD, or *1KGP_noIBS* populations. In the box plots, the
355 median, upper, and lower quartiles are represented by the centre line and box
356 bounds, respectively. Whiskers display the largest and smallest values within 1.5
357 times the interquartile range from the quartiles. Abbreviations: *1KGP_noIBS*, 1000 Genomes
358 Project without Iberian population; gnomAD*,* Genome Aggregation Database; *spain*, integration
359 of IBS and MGP populations.


Navarrese cohort
Analysis
Characterization
NAGEN1000
Rare diseases
N = 688 individuals (294 families)
Inclusion criteria:
• Unrelatedness
• Spanish ascendency
NAVARREsel cohort
358 WGS
127 affected
231 healthy
Variant calling:
Exonic biallelic SNVs: 61,410
Filtering: MAF > 1%
SNPs of Navarre: 21,174
Navarre Common SNVs
NAVARREsel: 1,069 SNVs
MAF > 1% in NAVARREsel
MAF < 1% in gnomAD · spain · 1KGP_noIBS
Validation
NAVARREval: 676 SNVs
239 WES
Effect on protein:
Missense: 371/676
Synonymous: 227/676
LoF: 5 /676
Clinical characterization:
ClinVar
OMIM
PharmGKB
Pathogenicity prediction
Enrichment analysis
KEGG
HPO
BP
DisGenet


NAVARRE
EUR
AMR
SAS
AFR
EAS
Superpopulation
AFR
AMR
EAS
EUR
NAVARRE
SAS
PCA2
PCA1
0.02
0.00
−0.02
−0.04
0.00
0.02
0.04


0.10
0.05
0.00
−0.05
−0.10
PCA2
−0.05
0.00
0.05
0.10
PCA1
NAVARRE
IBS
MGP
TSI
GBR
CEU
FIN
European Populations
CEU
FIN
GBR
IBS
MGP
NAVARRE
TSI


Common variants intersections
20000
15000
10000
5000
0
17532
2938
1140
1069
835
621
589
437
424
271
250
217
45
45
35
21177
20872
21871
23209
NAVARREsel
spain
1KGP_noIBS
gnomAD
20000
10000
0
Common variants per cohort


% resulting variants after filtering by MAF
5
4
3
2
1KGP_noIBS
spain
gnomAD
Navarre